Identification and characterization of psoralen and isopsoralen as potent cyp1a2 reversible and time-dependent inhibitors in human and rat preclinical studies

Drug Metabolism and Disposition

Volumn 41, Issue 11, 2013, Pages 1914-1922

  Zhuang, Xiao Mei ^a   Zhong, Yu Huan ^a   Xiao, Wei Bin ^a   Li, Hua ^a   Lu, Chuang ^b  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; ANGELICIN; CYTOCHROME P450 1A2; PHENACETIN; PSORALEN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG IDENTIFICATION; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIMULATION; SINGLE DRUG DOSE; TIME;

ANIMALS; AREA UNDER CURVE; CYTOCHROME P-450 CYP1A2; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; FICUSIN; HUMANS; MALE; MICROSOMES, LIVER; PHENACETIN; PSORALENS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84886492447     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.053199     Document Type: Article

References (50)

1. Apseloff G, Shepard DR, Chambers MA, Nawoot S, Mays DC, and Gerber N (1990) Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. Drug Metab Dispos 18:298-303.
2. Bachmann K, Sanyal G, Potter J, Schiavone R, and Loch J (1993) In vivo evidence that theophylline is metabolized principally by CYP1A in rats. Pharmacology 47:1-7.
3. Baumgart A, Schmidt M, Schmitz HJ, and Schrenk D (2005) Natural furocoumarins as inducers and inhibitors of cytochrome P450 1A1 in rat hepatocytes. Biochem Pharmacol 69: 657-667.
4. Bendriss EK, Bechtel Y, Bendriss A, Humbert PH, Paintaud G, Magnette J, Agache P, and Bechtel PR (1996) Inhibition of caffeine metabolism by 5-methoxypsoralen in patients with psoriasis. Br J Clin Pharmacol 41:421-424.
5. Cai Y, Bennett D, Nair RV, Ceska O, Ashwood-Smith MJ, and DiGiovanni J (1993) Inhibition and inactivation of murine hepatic ethoxy- and pentoxyresorufin O-dealkylase by naturally occurring coumarins. Chem Res Toxicol 6:872-879.
6. Chang RL, Wood AW, Huang MT, Xie JG, Cui XX, Reuhl KR, Boyd DR, Lin Y, Shih WJ, and Balani SK, et al. (2013) Mutagenicity and tumorigenicity of the four enantiopure bayregion 3,4-diol-1,2-epoxide isomers of dibenz[a,h] anthracene. Carcinogenesis DOI:10.1093/ carcin/bgt16 [published ahead of print].
7. Chinese Pharmacopoeia Commission (2010) Pharmacopoeia of the People's Republic of China, Traditional Chinese Medicines, Part 1 pp 174, People's Medical Publishing House Co Ltd, Beijing, China.
8. Chopra B, Dhingra AK, and Dhar KL (2013) Psoralea corylifolia L. (Buguchi) - Folklore to modern evidence: Review. Fitoterapia 90C:44-56.
9. Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, and Alberts DS (2010) Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 3:1168-1175.
10. Conforti F, Marrelli M, Menichini F, Menichini F, Bonesi M, Statti G, Provenzano E, and Menichini F (2009) Natural and synthetic furanocoumarins as treatment for vitiligo and psoriasis. Current Drug Therapy 4:38-58.
11. Dahlin DC, Miwa GT, Lu AY, and Nelson SD (1984) N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci USA 81: 1327-1331.
12. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
13. Distlerath LM, Reilly PE, Martin MV, Davis GG, Wilkinson GR, and Guengerich FP (1985) Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 260:9057-9067.
14. Edwards DJ, Bellevue FH, 3rd, and Woster PM (1996) Identification of 69,79-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab Dispos 24: 1287-1290.
15. Feng L, Wang L, and Jiang X (2010) Pharmacokinetics, tissue distribution and excretion of coumarin components from Psoralea corylifolia L. in rats. Arch Pharm Res 33:225-230.
16. Gu Y, Si D, Gao J, Zeng Y, and Liu C (2009) Simultaneous quantification of psoralen and isopsoralen in rat plasma by ultra-performance liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study after oral administration of Haigou Pill. J Chromatogr B Analyt Technol Biomed Life Sci 877:3137-3143.
17. Guo LQ, Taniguchi M, Xiao YQ, Baba K, Ohta T, and Yamazoe Y (2000) Inhibitory effect of natural furanocoumarins on human microsomal cytochrome P450 3A activity. Jpn J Pharmacol 82:122-129.
18. Guo LQ and Yamazoe Y (2004) Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol Sin 25:129-136.
19. Iwanaga K, Hayashi M, Hamahata Y, Miyazaki M, Shibano M, Taniguchi M, Baba K, and Kakemi M (2010) Furanocoumarin derivatives in Kampo extract medicines inhibit cytochrome P450 3A4 and P-glycoprotein. Drug Metab Dispos 38:1286-1294.
20. Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, and Hall SD (1999) Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 290:1116-1125.
21. Kang AY, Young LR, Dingfelder C, and Peterson S (2011) Effects of furanocoumarins from apiaceous vegetables on the catalytic activity of recombinant human cytochrome P-450 1A2. Protein J 30:447-456.
22. Lehr RE and Jerina DM (1977) Metabolic activations of polycyclic hydrocarbons. Structureactivity relationships. Arch Toxicol 39:1-6.
23. Li Y, Duan J, Guo T, Xie W, Yan S, Li B, Zhou Y, and Chen Y (2009) In vivo pharmacokinetics comparisons of icariin, emodin and psoralen from gan-kang granules and extracts of herba Epimedii, Nepal dock root, Ficus hirta yahl. J Ethnopharmacol 124:522-529.
24. Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, Balani SK, and Gan LS (2006) Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos 34:1600-1605.
25. Mann AM, Catterson AG, and MacPherson AS (1959) Toxicity of imipramine: report on serious side effects and massive overdosage. Can Med Assoc J 81:23-28.
26. Masubuchi Y and Horie T (1999) Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. Chem Res Toxicol 12:1028-1032.
27. Moody GC, Griffin SJ, Mather AN, McGinnity DF, and Riley RJ (1999) Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica 29:53-75.
28. Paine MF, Criss AB, and Watkins PB (2004) Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug Metab Dispos 32:1146-1153.
29. Paine MF, Criss AB, and Watkins PB (2005) Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J Pharmacol Exp Ther 312:1151-1160.
30. Parkinson A and Ogilvie BW (2008) Biotransformation of xenobiotics, in Casarett and Doull's Toxicology: The Basic Science of Poisons (Klaassen CD ed) pp 161-304, McGraw-Hill New York
31. Pearce DJ, Stealey KH, Balkrishnan R, Fleischer AB, Jr, and Feldman SR (2006) Psoriasis treatment in the United States at the end of the 20th century. Int J Dermatol 45:370-374.
32. Peterson S, Lampe JW, Bammler TK, Gross-Steinmeyer K, and Eaton DL (2006) Apiaceous vegetable constituents inhibit human cytochrome P-450 1A2 (hCYP1A2) activity and hCYP1A2-mediated mutagenicity of aflatoxin B1. Food Chem Toxicol 44:1474-1484.
33. Plowchalk DR and Rowland Yeo K (2012) Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. Eur J Clin Pharmacol 68:951-960.
34. Prince M, Campbell CT, Robertson TA, Wells AJ, and Kleiner HE (2006) Naturally occurring coumarins inhibit 7,12-dimethylbenz[a]anthracene DNA adduct formation in mouse mammary gland. Carcinogenesis 27:1204-1213.
35. Raaflaub J and Dubach UC (1975) On the pharmacokinetics of phenacetin in man. Eur J Clin Pharmacol 8:261-265.
36. Sessler CN and Cohen MD (1990) Cardiac arrhythmias during theophylline toxicity. A prospective continuous electrocardiographic study. Chest 98:672-678.
37. Shad MU (2008) Clozapine toxicity: A discussion of pharmacokinetic factors. Asian J Psychiatr 1:47-49.
38. Shimada T and Fujii-Kuriyama Y (2004) Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci 95:1-6.
39. Stern RS (2007) Psoralen and ultraviolet a light therapy for psoriasis. N Engl J Med 357: 682-690.
40. Stopher D and McClean S (1990) An improved method for the determination of distribution coefficients. J Pharm Pharmacol 42:144.
41. Tantcheva-Poór I, Servera-Llaneras M, Scharffetter-Kochanek K, and Fuhr U (2001) Liver cytochrome P450 CYP1A2 is markedly inhibited by systemic but not by bath PUVA in dermatological patients. Br J Dermatol 144:1127-1132.
42. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, and Miners JO (1994) Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2. Pharmacogenetics 4:281-284.
43. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
44. US Food and Drug Administration (2001) Guidance for Industry, Bioanalytical Method Validation. Available at: http://www.fda.gov/cder/guidance/ 4252fnl.pdf. Accessed August 30, 2013
45. Wang X and Morris ME (2008) Pharmacokinetics and bioavailability of the flavonoid 7,8- benzoflavone in rats. J Pharm Sci 97:4546-4556.
46. Wang Y, Hong C, Zhou C, Xu D, and Qu HB (2011) Screening antitumor compounds psoralen and isopsoralen from Psoralea corylifolia L. seeds. Evid Based Complement Alternat Med 2011:363052.
47. Wattanachai N, Tassaneeyakul W, Rowland A, Elliot DJ, Bowalgaha K, Knights KM, and Miners JO (2012) Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance. Drug Metab Dispos 40:982-989.
48. Weaver R, Graham KS, Beattie IG, and Riley RJ (2003) Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab Dispos 31:955-966.
49. Whiterock VJ, Morgan DG, Lentz KA, Orcutt TL, and Sinz MW (2012) Phenacetin pharmacokinetics in CYP1A2-deficient beagle dogs. Drug Metab Dispos 40:228-231.
50. Zhong Y, Shen G, Yuan M, Liu W, and Li H (2012) Evaluation of cytochrome P450 inhibition and induction by psoralen and isopsoralen in vitro. Chin J Pharmacol Toxicol 26:522-527.